HTGF Invests in Groundbreaking Innovation for Pain Therapy by Dolosys GmbH

Dolosys GmbH, a young spin-off of the Charité Department of Anaesthesiology and Intensive Care Medicine, receives financing from High-Tech Gründerfonds (HTGF) and m2f investment Ltd. The Berlin start-up has developed a pain monitor, which can optimize pain therapy for sedated intensive care patients and patients with chronic pain. Dolosys GmbH is going to use the seed investment to complete the development of the pain monitor and to market it after its successful certification as a medical device in 2014.

Only a year ago, the start-up team had submitted its business plan as an entry for the competitive ‘Science4Life Venture Cup’ and took fourth place. As a next step, the innovative idea and technology convinced the investors: particularly the determination of the optimal dosis of analgetics for sedated intensive care patients still poses a problem to modern medicine. To date, there is no device available which allows doctors to reliably determine the elimination of pain through opioides and other analgetics. For the estimation of the necessary doses, doctors still depend on the highly subjective evaluation and interpretation of the patients’ facial expressions and the posture of their extremities.

“In the future, the pain monitor will provide doctors with an objective and more specific criterion for the estimation of pain elimination. This enables individualized and precise pain therapy”, says the anaesthesiologist Dr. Jan Baars, the company’s managing director, praising the advantages of the device.

The reason why optimised pain therapy is so important, is that the application of overdoses as well as underdoses of opioides seriously stresses critically-ill intensive care patients, leads to additional complications and finally slows down patients’ recovery.

“Dolosys GmbH is developing a technology with the potential of moving pain therapy to the next level and becoming a new standard for treatment” explains Dr. Jung, Investment-Manager at HTGF, their reasons for financing the young business. “The technology is not only interesting for patients”, he adds, “but also for hospitals which profit from a shorter length of stay in the expensive intensive care units.”

Apart from the optimization of pain therapy for critically-ill intensive-care patients, Dolosys GmbH also expects the pain monitor to help chronic-pain patients in finding the optimal pain therapy.

About Dolosys GmbH
Dolosys GmbH is a medical technology business that focuses on the development and production of devices for the objective and individualised measuring of pain and pain elimination.
The method developed by Dolosys GmbH uses stimulated reflexes for the assessment of the analgesic effects of painkillers. Using the reflex bow, the method measures non-invasively the effect of pain medication on the decisive drug target, the spinal cord. This results in an estimation of pain elimination of so far unattained quality.
Dolosys GmbH spun off the Charité – Universitätsmedizin Berlin and has been sponsored since 2012 by the Federal Ministry for Economics and Technology (BMWi) through its research program “Exist Forschungstransfer”.

Contact:
Dr. Jan Baars
Dolosys GmbH
Nimrodstraße 90
13469 Berlin
phone: +49 177 753 8841
fax: 049 30 450 531 927
www.dolosys.de
info@dolosys.de

About HTGF
High-Tech Gruenderfonds invests in young, high potential high-tech start-ups. The seed financing provided is designed to enable start-ups to take an idea through prototyping and to market launch. Typically, High-Tech Gruenderfonds invests EUR 500,000 in the seed stage, with the potential for up to a total of EUR 2 million per portfolio company in follow-on financing. Investors in this public/private partnership include the Federal Ministry of Economics and Technology, the KfW Banking Group, as well as strategic corporate investors including ALTANA, BASF, B. Braun, Robert Bosch, CEWE Color, Daimler, Deutsche Post DHL, Deutsche Telekom, Evonik, Lanxess, media + more venture Beteiligungs GmbH & Co. KG, METRO, Qiagen, RWE Innogy, SAP, Tengelmann and Carl Zeiss. High-Tech Gruenderfonds has about EUR 573.5 million under management in two funds (EUR 272 million HTGF I, EUR 301.5 million HTGF II).

Contact:
High-Tech Gruenderfonds Management GmbH
Dr. Christian Jung
Investment Manager
Schlegelstraße 2
53113 Bonn
Tel: +49 228 823001-00
Fax: +49 228 823000-50
info@high-tech-gruenderfonds.de
https://www.htgf.de/